Cue Biopharma, Inc. (CUE) is a publicly traded company in the Healthcare — Biotechnology industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
Cue Biopharma, Inc. is a clinical-stage biopharmaceutical enterprise focused on creating biological therapies. Its central objective is the precise manipulation of the human immune system to address a spectrum of severe conditions, such as various cancers, chronic infectious diseases, and autoimmune disorders. The company's leading investigational therapeutic is CUE-101, a specialized fusion protein biologic.
Analysis Summary
Cue Biopharma, Inc. reported revenue of $27.5M in the most recent fiscal year, growing at a 5-year CAGR of 54.2%.
Trailing-twelve-month margins: gross margin 100.0%, operating margin -96.6%, net margin -96.9%.
At the current price of $34.17, CUE has negative trailing earnings (P/E not meaningful) and an ROE of -100.64%. Market capitalisation stands at $90M.
Balance sheet quality for CUE: current ratio of 2.7, net cash position of $22.9M. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Price
| Price | $34.17 |
| Market Cap | $90M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 1.34 |
| EV / EBITDA | -0.27 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -100.64% |
| Return on Invested Capital | -86.59% |
| Return on Assets | -63.02% |
| Gross Margin | 100.00% |
| Operating Margin | -96.56% |
| Net Margin | -96.85% |
Financial Health
| Debt / Equity | 0.16 |
| Current Ratio | 2.74 |
| Piotroski F-Score | 4 |
| Altman Z-Score | -11.88 |
What to look at in Biotech
Most small biotechs lose money. Analysing them with P/E makes no sense — look at cash and pipeline.
- Cash Runway — Months of cash at current burn rate. <18 months = urgent dilution risk
- Annual cash burn — Rate at which they burn operating cash. Compare with cash position to project runway
- Total Debt — Biotech with no revenue + debt = recipe for bankruptcy
- R&D / Market cap — How much they invest in pipeline vs the company value — research-intensity indicator
- Market cap / Cash — If it trades near its cash, the market assigns ~0 value to the pipeline — opportunity or trap
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| CUE | Cue Biopharma, Inc. | $90M | 1.34 | -100.6% | |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.8B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $130.6B | 29.76 | 6.46 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.0B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $79.8B | 18.79 | 2.57 | 13.8% |
| ARGX | argenx SE | $61.2B | 36.30 | 7.40 | 21.7% |
| MRNA | Moderna, Inc. | $57.8B | 1.34 | -39.2% | |
| RVMD | Revolution Medicines, Inc. | $41.7B | 15.96 | -96.4% |
Price Performance
| 1 month | +32.96% |
| 3 months | +20.06% |
| Year-to-date | +273.03% |
| 1 year | +57.68% |
| 3 years | -52.54% |
| 5 years | -91.18% |
52-Week Range
| 52-week High | $45.50 |
| 52-week Low | $4.97 |
| Avg Volume (90d) | 149K |
Related companies: BRNS · COEP · EQ · IOBT · IPSC · MDCX · NRXP
Explore sector: Healthcare · Biotechnology
More sections of CUE: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks